Plasma protein binding displacement interactions--why are they still regarded as clinically important?
about
Aging and the environment: a research frameworkOn the Slow Diffusion of Point-of-Care Systems in Therapeutic Drug MonitoringA structure-based model for predicting serum albumin bindingClinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancerSingle-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function.Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosingIn vivo effect of alpha(1)-acid glycoprotein on pharmacokinetics of amprenavir, a human immunodeficiency virus protease inhibitor.The antimalarial drug halofantrine is bound mainly to low and high density lipoproteins in human serum.Drug-drug interactions between warfarin and psychotropics: updated review of the literature.Clinical pharmacology and pharmacokinetics of amprenavir.In silico prediction of human serum albumin binding for drug leads.Interaction of warfarin with drugs, natural substances, and foods.Binding of propofol to blood components: implications for pharmacokinetics and for pharmacodynamics.Drug bioactivation, covalent binding to target proteins and toxicity relevance.Interactions between herbal and conventional medicines.Pharmacokinetic/pharmacodynamic modeling of anesthetics in children: therapeutic implications.Antidepressant-drug interactions are potentially but rarely clinically significant.Clopidogrel variability: role of plasma protein binding alterationsToxicology and pharmacokinetics of 1-methyl-d-tryptophan: absence of toxicity due to saturating absorption.Probable drug interaction between warfarin and hormonal contraceptives.The effect of liver disease on inhibitory and plasma protein-binding displacement interactions: an update.Duloxetine: clinical pharmacokinetics and drug interactions.Plasma protein binding and blood-free concentrations: which studies are needed to develop a drug?Detrimental effects of divalproex on warfarin therapy following mechanical valve replacement.Hemarthrosis in a patient on warfarin receiving ceftaroline: a case report and brief review of cephalosporin interactions with warfarin.Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties.Clinical pharmacology of deferasirox.Pharmacokinetic considerations for drugs administered in the critically ill.Use of Antiepileptic Drugs in Patients with Chronic Kidney Disease and End Stage Renal Disease.Antibiothérapie du sujet âgé : On peut toujours mieux faire.Brivaracetam population pharmacokinetics in children with epilepsy aged 1 month to 16 years.New prodrugs of the antiprotozoal drug pentamidine.Breast-cancer diagnosis by neuropeptide Y analogues: from synthesis to clinical application.Significance of admission hypoalbuminemia in acute intracerebral hemorrhage.Evaluation of a Potential Interaction Between New Regimens to Treat Hepatitis C and Warfarin.The investigation of the binding of 6-mercaptopurine to site I on human serum albumin.The effect of multiple doses of donepezil HCl on the pharmacokinetic and pharmacodynamic profile of warfarin.Higher clearance of micafungin in neonates compared with adults: role of age-dependent micafungin serum binding.Moxifloxacin-warfarin interaction.Symptomatic hypoglycemia associated with trimethoprim/sulfamethoxazole and repaglinide in a diabetic patient.
P2860
Q24815677-8A2A43DC-A5B9-423D-BD41-DE461BA64CF7Q27024074-862FEA1B-0E2B-4E40-90AA-C880D7B623F7Q28541718-58E83A1B-CB95-4E91-9901-905924FFD331Q29006772-E143D5D6-C236-4654-AA66-309CC595AF48Q33979074-EB4C5B29-EF38-4FB3-96BA-FB1F7DA90C8FQ33981100-84D97922-1F84-4EB2-82CD-BF842DDB981DQ33981674-991A6448-20C5-4FB9-B735-0A5978AEEB04Q34347239-74B3DA06-09D3-4FF4-B3C6-7DF30A6EDBA8Q34432843-4FAB00ED-831B-4788-B8BA-8930F60D9FC1Q34509359-11DD93E0-DD97-4B41-920A-592F381EFD5EQ34609144-01BB1D1C-84E3-4EF5-B7AF-CA33C8A798EBQ36007599-85B51FDA-FF3F-4812-B740-919E8ED5146CQ36053289-F77BB89A-75C4-4C53-972D-45336E6A39BAQ36061821-9CDE918C-4CA8-4DA8-8AD9-F78CB602EFA5Q36082038-8A926318-7598-4268-9E86-CD99C05D128DQ36506764-1A822B3D-4CC7-490E-836A-43DAB908ADF6Q36538987-189718BE-F31C-419E-80D4-303FF45F2CD3Q36948114-490CC636-4E02-42A1-8F23-2AB78D122612Q37347671-0A8DF1A1-E225-4BC8-ABF9-6CE5DC328314Q37637747-ABE5D020-5DA0-4CBB-AAB3-1BFBD8647D0EQ37770251-6D9F354A-EFCA-4C8C-AE43-EAEE5D5F8E37Q37848815-99FD1E47-EF45-4A45-8929-403DBFBA77CCQ37884058-9757BA6F-78C8-45D6-8005-21020216368EQ37920925-0FDE1574-6E70-4110-B388-20FA532FCF0FQ38024092-BCF0DA2B-72BF-419C-BF09-1ADB38AE9DE5Q38151563-7E206299-AA7C-441C-A9FB-3AF4C34977A2Q38226394-EC102AB6-0954-4FA8-A325-5BD67531B0E0Q38351793-1A2D6870-750D-421F-98E3-44A0EE870029Q38451960-FE3999D8-EDD7-45D0-BECF-D569902706D2Q38862567-9454AF6C-1873-49AE-BD66-E035A368A242Q38915714-6CF4784C-2ADD-435B-9423-2BF0D3789CDDQ39460980-94410C9B-6FC5-4CB2-A6CA-D1D45994C599Q39747426-BBAE47C0-D63E-4A6D-9C72-2A692F9AF43FQ40298635-9D6B9569-FFCE-45D7-8752-F05B8939316CQ40597366-1ADFF33D-2341-4500-B858-D9ED84C0CC7CQ41652521-30086821-7A33-4568-B56E-6AAA607C81E5Q42024371-AB2283F8-C686-4999-B7AC-DD08C3DB77CEQ42720364-61A82A68-0BBE-4C64-9FAE-13ED58ACE034Q43088152-58D60714-3249-4EB4-AF77-9B098D166BBEQ43144700-5AC5BEBA-7B65-44B4-95C1-2A018A4C773F
P2860
Plasma protein binding displacement interactions--why are they still regarded as clinically important?
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Plasma protein binding displac ...... arded as clinically important?
@en
type
label
Plasma protein binding displac ...... arded as clinically important?
@en
prefLabel
Plasma protein binding displac ...... arded as clinically important?
@en
P2860
P1476
Plasma protein binding displac ...... arded as clinically important?
@en
P2093
P2860
P304
P356
10.1111/J.1365-2125.1994.TB04251.X
P407
P577
1994-02-01T00:00:00Z